Skip to main content
. 2020 Oct 13;11(10):847. doi: 10.1038/s41419-020-03046-z

Fig. 4. GSK2606414 decreases the expression of osteoclast marker genes and inhibits RANKL-induced NF-κB and MAPKs activation.

Fig. 4

a–c BMMs were treated with GSK2606414 (0.1 μM) in the presence of RANKL (100 ng/mL) and M-CSF (30 ng/mL) for 2 or 4 days. p-PERK, PERK and osteoclast-related marker genes proteins expression were measured by western blot at the indicated times and mRNA levels were determined by RT-PCR. d–g BMMs were starved with a-MEM in the absence of FBS for 12 h, pretreated with or without GSK2606414 for 2 h. After that, BMMs were treated with or without RANKL (100 ng/mL) for the indicated times. The total proteins were extracted and western blot was conducted to detect the expression of NF-κB and MAPK signaling pathways. Densitometric analysis of an immunoblot from three independent experiments; *p < 0.05, **p < 0.01.